Call scheduled for Tuesday, August 14 at 10:30am Eastern Time.
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage medical device
and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory
conditions including serious lung infections and pulmonary hypertension, today announced it will report financial results for its
fiscal first quarter ended June 30, 2018 before the market open on Tuesday, August 14, 2018 and will host a conference call and
webcast at 10:30am Eastern Time.
| Conference Call &
Webcast |
| Tuesday, August 14th @ 10:30am
Eastern Time |
| Domestic: |
800-479-1004 |
| International: |
323-794-2599 |
| Passcode: |
6914488 |
| Webcast: |
http://public.viavid.com/index.php?id=130799
|
| |
|
| Replays available through August
28th: |
| Domestic: |
844-512-2921 |
| International: |
412-317-6671 |
| Conference ID: |
1819673 |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory
and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections
that are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings.
AIT Therapeutics is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of
bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com
Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597 6989
